234 results
424B4
SNGX
Soligenix Inc
19 Apr 24
Prospectus supplement with pricing info
4:05pm
compared to placebo with positive long-term (12 month) safety also reported; Phase 3 clinical trial results announced December 2020: the primary endpoint … of intellectual property infringement by a third party.
Our near and long-term prospects depend in part on our ability to obtain and maintain
8-K
EX-99.2
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
) (Blinded)
➢ Because of chronic nature of early stage CTCL and long-term treatment cycles, clinicians choose therapies with better safety profiles first
8-K
EX-99.1
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
effect over a more prolonged, “real world” treatment course.
“In treating CTCL, which is a chronic cancer with no cure, long-term safety is a strong … is an orphan disease in urgent need of additional treatment options that are well-tolerated and safe over the long term,” stated Christopher Schaber, PhD
424B4
1hiq5
5 May 23
Prospectus supplement with pricing info
6:43pm
8-K
EX-99.1
npugktf68i d1dqx7
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am